title: Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
abstract: OBJECTIVE
  To assess the feasibility and toxicity of consolidative intensity-modulated whole abdominal radiotherapy (WAR) after surgery and chemotherapy in high-risk patients with advanced ovarian cancer.
  
  
  METHODS
  Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1.5-Gy fractions as consolidation therapy after adjuvant carboplatin/taxane chemotherapy. Treatment was delivered using intensity-modulated radiotherapy in a step-and-shoot technique (n = 3) or a helical tomotherapy technique (n = 7). The planning target volume included the entire peritoneal cavity and the pelvic and para-aortal node regions. Organs at risk were kidneys, liver, heart, vertebral bodies, and pelvic bones.
  
  
  RESULTS
  Intensity-modulated WAR resulted in an excellent coverage of the planning target volume and an effective sparing of the organs at risk. The treatment was well tolerated, and no severe Grade 4 acute side effects occurred. Common Toxicity Criteria Grade III toxicities were as follows: diarrhea (n = 1), thrombocytopenia (n = 1), and leukopenia (n = 3). Radiotherapy could be completed by all the patients without any toxicity-related interruption. Median follow-up was 23 months, and 4 patients had tumor recurrence (intraperitoneal progression, n = 3; hepatic metastasis, n = 1). Small bowel obstruction caused by adhesions occurred in 3 patients.
  
  
  CONCLUSIONS
  The results of this Phase I study showed for the first time, to our knowledge, the clinical feasibility of intensity-modulated whole abdominal radiotherapy, which could offer a new therapeutic option for consolidation treatment of advanced ovarian carcinoma after adjuvant chemotherapy in selected subgroups of patients. We initiated a Phase II study to further evaluate the toxicity of this intensive multimodal treatment.
authors.affiliation: Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany. nathalie.rochet@med.uni-heidelberg.de
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rochet
authors.forename: Florian
authors.initials: F
authors.lastname: Sterzing
authors.forename: Alexandra D
authors.initials: AD
authors.lastname: Jensen
authors.forename: Julien
authors.initials: J
authors.lastname: Dinkel
authors.forename: Klaus K
authors.initials: KK
authors.lastname: Herfarth
authors.forename: Kai
authors.initials: K
authors.lastname: Schubert
authors.forename: Michael H
authors.initials: MH
authors.lastname: Eichbaum
authors.forename: Andreas
authors.initials: A
authors.lastname: Schneeweiss
authors.forename: Christof
authors.initials: C
authors.lastname: Sohn
authors.forename: Juergen
authors.initials: J
authors.lastname: Debus
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Harms
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D003967:Diarrhea / Q000209:etiology; D019583:Dose Fractionation, Radiation; D005240:Feasibility Studies; D005260:Female; D006321:Heart / Q000528:radiation effects; D006801:Humans; D007668:Kidney / Q000528:radiation effects; D007970:Leukopenia / Q000209:etiology; D008099:Liver / Q000528:radiation effects; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D010384:Pelvic Bones / Q000528:radiation effects; D011446:Prospective Studies; D011832:Radiation Injuries / Q000517:prevention & control; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods*; D013131:Spine / Q000528:radiation effects; D013921:Thrombocytopenia / Q000209:etiology
chemical_list: D016190:Carboplatin